Tower Research Capital (TRC)’s VITAE PHARMACEUTICALS INC COMMON STOCK VTAE Stock Holding History

Tower Research Capital (TRC)’s Portfolio VTAE Stock Details VTAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-726	Closed	-$15K	–	4934
2016 Q3	$15K	Sell	726 -640	-47%	-$7.37K	﹤0.01%	1819
2016 Q2	$15K	Buy	1,366 +543	+66%	+$4.64K	﹤0.01%	2512
2016 Q1	$5K	Buy	823 +51	+7%	+$464	﹤0.01%	2824
2015 Q4	$14K	Buy	+772	New	+$10.6K	﹤0.01%	1748
2015 Q3	–	Sell	-3,073	Closed	-$44K	–	5359
2015 Q2	$44K	Buy	+3,073	New	+$41.7K	﹤0.01%	1480
2015 Q1	–	Sell	-2,992	Closed	-$50K	–	5325
2014 Q4	$50K	Buy	2,992 +2,852	+2,037%	+$41.7K	﹤0.01%	1038
2014 Q3	$1K	Buy	+140	New	+$1.09K	﹤0.01%	4264

Tower Research Capital (TRC)'s VTAE Position: Q4 2016 in Review

Tower Research Capital (TRC) sold out of VITAE PHARMACEUTICALS INC COMMON STOCK (VTAE) in Q4 2016, closing a stake of 726 shares — an estimated $15K sold.

Tower Research Capital (TRC) first reported a position in VTAE in Q3 2014 and held it in 7 quarters. The position peaked at $50K in Q4 2014. 0 funds tracked by Wall St. Rank hold VTAE as of Q4 2016.

Tower Research Capital (TRC) reported no remaining VITAE PHARMACEUTICALS INC COMMON STOCK position as of Q4 2016 after selling out during the quarter.
Tower Research Capital (TRC) sold 726 VITAE PHARMACEUTICALS INC COMMON STOCK shares in Q4 2016, an estimated $15K.
Tower Research Capital (TRC) first reported a position in VITAE PHARMACEUTICALS INC COMMON STOCK in Q3 2014 and held it in 7 quarters.
Tower Research Capital (TRC)'s VITAE PHARMACEUTICALS INC COMMON STOCK position peaked at $50K in Q4 2014.
0 funds tracked by Wall St. Rank held VITAE PHARMACEUTICALS INC COMMON STOCK as of Q4 2016.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2016, filed 3 Feb 2017.